Myelodysplastic Syndromes – Causes, Symptoms, and Treatment Options

Myelodysplastic syndromes (MDS) represent a group of complex hematological disorders characterized by the deficient production of blood cells in the bone marrow. This disease can significantly affect general well-being, but a thorough understanding of it, along with available treatment options, can contribute to more effective symptom management and improved prognosis.

In this article, you will find essential information about myelodysplastic syndrome, from its causes and manifestations to diagnostic methods and therapeutic alternatives. You will also discover ways to support overall health during this condition.

What is myelodysplastic syndrome?

Myelodysplastic syndrome (MDS) is a group of diseases in which the bone marrow no longer produces enough functional blood cells. Essentially, the stem cells in the bone marrow become dysfunctional, leading to the generation of abnormal or underdeveloped blood cells. This dysfunction can lead to serious complications, affecting quality of life.

The main characteristics of MDS include:

• Reduced production of blood cells (cytopenia).
• Blood cells with abnormal appearance and function (dysplasia).
• An increased risk of progression to acute myeloid leukemia.

Although MDS is more commonly encountered in older adults, with a median age at diagnosis around 70 years, the condition can also occur in children and young adults. It is important to be aware of risk factors and to recognize symptoms to facilitate early diagnosis and appropriate management.

Causes and risk factors of myelodysplastic syndrome

The exact causes of MDS are not fully understood, but there are several identified risk factors that can contribute to the development of this complex condition. Understanding these factors is important for evaluating individual risk and adopting preventive measures where possible.

• Advanced age: risk significantly increases after 60 years.
• Exposure to certain toxic chemicals, such as benzene or certain pesticides.
• Previous cancer treatments, particularly chemotherapy or radiation therapy.
• Certain inherited genetic conditions, such as Fanconi anemia.
• Smoking: it contains harmful substances that can affect bone marrow.

It is important to note that the presence of one or more risk factors does not necessarily mean you will develop MDS. Many people with these factors never develop the disease, while others may be diagnosed with MDS even in the absence of any known risk factor. Therefore, regular monitoring and a healthy lifestyle are essential for maintaining bone marrow health.

Symptoms of myelodysplastic syndrome

MDS symptoms can vary considerably, from mild to severe manifestations, and are often correlated with the types of blood cells affected. This variability can sometimes make early diagnosis difficult, but recognizing the symptoms is an important step in seeking appropriate medical attention.

• Extreme fatigue and general weakness (caused by anemia).
• Shortness of breath upon exertion.
• Pale skin.
• Unusual bleeding or frequent bruising (caused by thrombocytopenia).
• Frequent or severe infections (caused by neutropenia).

In the early stages of the disease, you may not notice any symptoms. In some cases, MDS is discovered incidentally during regular blood tests. Therefore, it is essential to pay attention to any changes in your health status and consult a doctor for evaluation, especially if you have known risk factors.

Impact

The symptoms of myelodysplastic syndrome can have a significant impact on quality of life, and maintaining adequate nutritional balance plays a crucial role in supporting the body against these challenges. In the context of deficient cellular metabolism, characteristic of MDS, deficiencies in essential vitamins, particularly from the B complex group, which are directly involved in the blood cell formation process and nervous system function, can occur.

In such situations, a quality nutritional supplement, such as Premium Aronia Vitamin B-Complex, can be helpful. This product combines essential B vitamins (B1, B2, B3, B5, B6, B9, B12) with vitamin C and aronia extract, known for its antioxidant effect. Through this formula, it supports cellular metabolic processes, contributes to reducing fatigue, and supports immune function – essential aspects for individuals with MDS.

Using such a complex can supplement the diet and help the body better cope with oxidative stress, hematological imbalances, and the overall impact of the disease. Of course, any supplement should be introduced after medical consultation, to be adapted to the needs and treatment of each patient.

Photo source: Aronia-charlottenburg.ro

Diagnosis of myelodysplastic syndrome

Diagnosing MDS involves a series of investigations and procedures aimed at assessing the state of the bone marrow and blood cells. These tests are essential to determine the specific type of MDS and to rule out other conditions with similar symptoms.

• Complete blood count (CBC): to evaluate the number and appearance of blood cells.
• Microscopic examination of peripheral blood smear: to identify possible morphological abnormalities of the cells.
• Bone marrow aspiration and biopsy: to examine the bone marrow cells.
• Cytogenetic tests: to identify chromosomal abnormalities.
• Molecular tests: to detect specific genetic mutations.

These investigations help doctors determine the specific type of MDS and assess the severity of the disease, which are essential aspects for planning appropriate treatment. Once a diagnosis is established, various therapeutic options can be explored.

Treatment options for myelodysplastic syndrome

The therapeutic approach in MDS is tailored according to the type and severity of the disease, as well as the patient’s general health status. The main goal of treatment is to alleviate symptoms and improve quality of life. In some cases, to slow disease progression or induce remission.

• Supportive therapy: blood transfusions, antibiotics to combat infections.
• Erythropoiesis-stimulating agents (ESAs): to stimulate red blood cell production.
• Hypomethylating agents: azacitidine or decitabine, to improve blood cell production.
• Lenalidomide: particularly effective for MDS with 5q deletion.
• Chemotherapy: used in severe cases or when the disease progresses to leukemia.
• Stem cell transplantation: the only potentially curative option, but not suitable for all patients.

Treatment is often personalized and may involve a combination of different approaches. It is important to discuss the most suitable therapeutic options for your specific situation with your hematologist. Additionally, adopting a healthy lifestyle, which includes a balanced diet and appropriate nutritional supplements, can help support the body during treatment.

Life expectancy and prognosis in myelodysplastic syndrome

The prognosis in myelodysplastic syndrome (MDS) – a form of myelodysplasia characterized by defective blood cell production – can vary considerably, being influenced by a series of factors including: the specific type of MDS, the patient’s age and general health status, the genetic abnormalities present, and the response to treatment.

This hematological disorder often manifests as medullary dysplasia, meaning morphological changes in the precursor cells in the bone marrow. These lead to the deficient formation of red blood cells, white blood cells, and platelets. In some cases, the bone marrow may show medullary hypoplasia, meaning a reduction in cell production activity, which exacerbates the clinical picture.

Another frequently encountered subtype is refractory anemia, where the body does not respond adequately to iron supplementation or routine treatments, and anemia persists due to profound impairment of medullary erythropoiesis.

Prognostic assessment is essential for adapting the treatment plan and providing patients with realistic information about the disease’s progression. The determining factors include:

• The specific type of MDS;
• The patient’s age and general health status;
• The genetic abnormalities present;
• The response to treatment.

Prognostic scoring systems, such as IPSS-R (Revised International Prognostic Scoring System), help doctors estimate life expectancy and the risk of progression to acute myeloid leukemia. Life expectancy can range from a few months to over 10 years, depending on the risk category.

It is important to remember that these estimates represent statistical averages and that individual prognosis can vary significantly. Thanks to advances in available treatments – including supportive therapies, hypomethylating drugs, and stem cell transplantation – many people with MDS today live longer than initial estimates. Enjoying an improved quality of life even in the presence of complex myelodysplasia.

Myelodysplastic syndrome is a complex condition, but a thorough understanding of its causes, symptoms, and treatment options can make a significant difference in managing the disease. Regular monitoring, a healthy lifestyle, and close collaboration with the medical team are essential for improving prognosis and quality of life. The next important step is to discuss personalized treatment options with your doctor. And ways to support your body during therapy. Remember that advances in research offer new hope and continuously improve outlooks for patients with MDS.

References

• https://my.clevelandclinic.org/health/diseases/6192-myelodysplastic-syndrome-myelodysplasia
• The Myelodysplastic Syndromes (MDS) Foundation: mds-foundation.org
• https://www.mayoclinic.org/diseases-conditions/myelodysplastic-syndrome/symptoms-causes/syc-20366977